Generic formulation development, manufacturing and marketing

We have a cGMP complaint R&D facility for formulation manufacturing, testing and development. We also have the capability to develop formulations along with requisite BA/BE studies, regulatory services and filing of the ANDAs. We also contract manufacture the developed formulations for US and ROW markets. Our present reach of marketing formulations expands across Singapore, Malaysia and South Africa and various other countries through partnerships. We have already achieved 12% market share in majority of the launched products and more than 35% to 50% market share in other niche products. The generic formulations manufactured by Indian manufacturers are marketed by THINQ/RISING under exclusive marketing agreements in the US market. Currently we have more than a dozen prescription products being sold under our label in the U.S. market and more than 30 products under development.”

APIs, CRAMS and Adv. Intermediates Development and Marketing

With extensive knowledge of pharmaceutical ingredients over the past 25 years we can say with confidence that we have the ability to develop complex chemistry. In the past, we have had Mr. Robert Grubbs, a renowned Nobel Laureate, on our Technical Board. We have worked with almost all MNCs, including Japanese companies developing CRAMs and intermediates with complicated technology. We also develop products on exclusive basis in our R&D Centre which is well equipped with modernized, latest equipment required for developing Pharma APIs and Intermediates. Our R&D Centre is over 300 Sq. Mts. and is now being expanded by another 400 Sq. Mts. We have efficiently handled the development of 12 products simultaneously in a confidential and exclusive basis. We have the capacity to take up 10-12 projects simultaneously. We also have the capability to manufacture advance and bulk intermediates on multi ton level under Exclusive and Confidentiality Agreements with our associate Indian manufacturers having cGMP compliance. THINQ is well positioned to emerge as an outsourcing partner of choice due to desire for innovation, quest for quality, optimal utilization of capacities and highly efficient supply chain management. Our experts can guide the customer through all the phases of analytic support required. We can also work with customers whose product is under development during commercial manufacturing or consider them for independent analytical services. We are able to quickly and efficiently deliver results that meet your needs, while combining high quality standards with sustainability, at competitive prices.

Types of Reactions handled
Asymmetric & Catalytic hydrogenation. Wittig Reaction
Friedel-Craft reactions Halogenation
‘Pd’ catalyzed couplings like Suzuki/Sonogashira/Buchwald etc. High vacuum distillation
Base catalyzed reactions including LDA, BuLi etc. High pressure & High temperature reactions
Grignard reactions Chiral resolutions
Heck Reaction Nitration/sulfonation/ Chloro sulfonation
Cryogenic reactions up to -400C  

More

Clinical studies and Clinical data management

Established in 2003, our CRO business has gained primary importance in the services that we provide. We were the first Indian CRO to produce and implement Oracle Clinical, thereby enabling improved operational efficiency and productivity even in complex trial design scenarios. Our top priority is to maintain consistent data quality that includes functionality across multiple areas: Trial Budgeting, Regulatory Affairs, Data Management, Pharmacovigilance in collaboration with our associates, Medical Writing, Clinical Operations and Statistical Analysis.

Regulatory Services

We have the expertise to provide expert clinical and regulatory support through all phases of global drug development to commercialization, from BA/BE Analysis to Quality cGMP compliance. We prepare all regulatory documentation including filing of DMFs, ANDAs and maintaining post approval change management. Our proficiency in organizing quality dossiers ensures timely approvals. We have the bandwidth to support clinic and regulatory activities across USA, EU, Asia Pacific and Latin America.